# TKA adjunct analgesia: selected evidence and interpretation

> **Educational work by a pre-medical student — not medical advice.** Not a clinical protocol, prescription, or patient handout, and not for patient care. See [DISCLAIMER](DISCLAIMER.md).

**Independent educational portfolio. Revised 27 October 2026.** This note replaces the earlier dose-based opioid-free pathway discussion after source inconsistencies were identified. It is a selected-source analysis, not a clinical pathway, systematic review, or validated device input.

## Define the comparison

Avoiding opioids during surgery differs from eliminating all perioperative opioids. Postoperative rescue, background spinal/regional analgesia and other medicines must be described before comparing outcomes. A reduction in opioid use does not alone establish better pain control, function, safety or prevention of long-term opioid use.

## Procedure-specific guidance

[PROSPECT 2022, PMID 35852550](https://pubmed.ncbi.nlm.nih.gov/35852550/) supports a multimodal TKA framework and evaluates each intervention within that context. It does not recommend routine gabapentinoids, and it does not recommend ketamine, citing conflicting procedure-specific evidence. Its procedure-specific conclusions should not be replaced by generic mixed-surgery efficacy claims. This summary does not reproduce the guideline or its exceptions.

## An informative randomized trial

[Muñoz-Leyva et al., "No Benefits of Adding Dexmedetomidine, Ketamine, Dexamethasone, and Nerve Blocks to an Established Multimodal Analgesic Regimen after Total Knee Arthroplasty," *Anesthesiology* 2022;137(4):459-470, PMID 35867857](https://pubmed.ncbi.nlm.nih.gov/35867857/) randomized 78 TKA patients to an established regimen with or without five additional interventions, including ketamine, dexmedetomidine and additional regional/anti-inflammatory components. It did not demonstrate further benefit in opioid consumption, pain or recovery and reported more hypotension in the add-on group.

Because several interventions changed together, the trial cannot determine each component's independent effect. A nonsignificant difference is not equivalence, non-inferiority or proof of zero benefit. The results apply to the studied population and background regimen.

## Lidocaine and regional anesthesia

[Foo et al., international consensus](https://doi.org/10.1111/anae.15270) addresses perioperative IV lidocaine safety. It should not be treated as a universally safe adjunct to local-anesthetic blocks. This portfolio supplies no infusion rates, timing intervals or combined-local-anesthetic regimen.

## Withdrawn assertions

The earlier document cited PMID 23364596 as a Farag TKA lidocaine trial. That identifier does not correspond to a TKA lidocaine trial, so the claimed trial results are removed. The previous unsupported numerical efficacy estimates, fixed patient-selection criteria, processed-EEG safety guarantee, GRADE A–D labels and medication dosing are also withdrawn rather than retained behind a disclaimer.

No robot-assisted TKA efficacy, absence of all relevant trials, FDA regulatory classification or patient-level treatment recommendation is asserted. Other documents in the series retain their own source-audit requirements.